The largest randomized study of fluid intake restrictions showed no benefit from the restrictions, according to its senior ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

CHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

The “neutral” trial, troubled by the COVID-19 pandemic, found that intensive medical therapy didn’t lower events in INOCA.

Three months of dual antiplatelet therapy after PCI may safely balance thrombosis and bleeding risk in both patients with low ...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...

GE HealthCare is also using ACC 2025 to highlight new AI-powered innovations for cardiac care: The latest version of CASE (Cardiac Assessment System for Stress Testing), powered by the company’s ...

The first clinical guidance for cardiogenic shock will be presented at the American College of Cardiology Scientific Session ...